Balsu’s best sentence begins with a hazelnut shell. Under the Hendex brand, the company describes turning shells into activated carbon, replacing imported product with a domestic, high value-added material, and even generating energy from synthesis gas extracted from hazelnut shells. This is a real industrial option; the annual report speaks of an investment incentive revised to 3.074 billion TL, a 22 thousand square meter factory area, and a capacity target above 20 thousand tons per year for 2026-2028.
But that is not the sentence carrying the stock today. Today’s sentence is on the balance sheet: 14.30 billion TL of financial debt, 421.6 million TL of cash and financial investments, 13.88 billion TL of net debt. Equity is 4.40 billion TL. In other words, the shell has not yet become carbon; the debt is already 3.15 times capital.
The company’s scale should not be underestimated. The annual report gives 2024 sales volume as 49,035 tons; this volume corresponds to 13 percent of Turkey’s production in kernel hazelnut equivalent. The Hendek and Ordu facilities, the sales legs in the US-Germany-Hong Kong-Chile, wholly owned foreign subsidiaries, and BG Holding’s 75 percent control all move Balsu beyond being a small agricultural company. There is a real global supply system here.
But the financial nature of this system is not romantic. In the hazelnut business, when the inventory and receivables ledger grows, working capital becomes the company’s second factory. In the 2025Q3 balance sheet, inventories are 10.71 billion TL and trade receivables are 8.27 billion TL. Together, these two items are 4.31 times equity. Every new ton is not only sales; it is credit, maturity, currency, interest, and harvest timing.
| Item | Amount / ratio |
|---|---|
| Inventories | TRY 10.71bn |
| Trade receivables | TRY 8.27bn |
| Inventories + receivables / equity | 4.31x |
| Financial debt | TRY 14.30bn |
| Cash + financial investments | TRY 0.42bn |
| Net debt / equity | 3.15x |
The Factory’s Earnings Pass Through the Bank
The KAP financials show two different BALSUs at first glance. The first is the working factory: 2025/9 revenue of 15.27 billion TL, gross profit of 2.18 billion TL, and pre-financing operating profit of 1.53 billion TL. The third quarter alone is stronger still: 7.58 billion TL in sales, 1.23 billion TL in gross profit, and 697.6 million TL in net profit.
The second is the balance sheet that runs on debt: in the same nine months, financial expense was 2.92 billion TL. This amount is 1.34 times nine-month gross profit. Without the 946.8 million TL monetary position gain from inflation accounting and the 41.7 million TL deferred tax income, the loss would have looked harsher. Even so, the parent-company share posted a 160.8 million TL loss.
That is why reading BALSU only through a seemingly low profitability multiple is dangerous. If you multiply Q3 net profit by four, the market value looks cheap at roughly 5.6x annualized earnings. But the main nine-month picture records a loss; operating cash flow in the same period is also 2.07 billion TL negative. Inside that negative cash flow sits a 3.87 billion TL increase in trade receivables and a 3.06 billion TL increase in inventories. The 6.06 billion TL increase in trade payables gave the company air, but this air is not equity; it is maturity.
The good news for the company is this: Q3 cash flow from operating activities was 1.49 billion TL positive. The bad news is this: the share price now wants that improvement to be permanent. This distinction is not small. If the seasonal inventory cycle normalizes, receivables turn, and financial debt falls, the balance sheet can suddenly look more reasonable. If the opposite happens, no matter how good operating profit is, the shareholder waits behind the bank and supplier credit.
The Option Is Real, But Not Free
The Hendex and Chile plans prove that BALSU is not an ordinary hazelnut trader. For the Chile facility, annual processing capacity above 20 thousand tons is targeted; the report says permits have been received, projects approved, and roughly 60 percent of the ordered machinery completed. On the Hendex side, the activated carbon investment aims to turn hazelnut shells into a product used in purification, filtration, energy storage, mining, and defense.
| Topic | Evidence |
|---|---|
| Chile plant | Target processing capacity above 20 thousand tons per year; planned start in 2026 |
| Machines and permits | Permits obtained; projects approved; roughly 60% of ordered machinery completed |
| Hendex incentive | Planned fixed investment amount revised to TRY 3.074bn |
| Active carbon capacity | Target capacity above 20 thousand tons per year during 2026-2028 |
| Rooftop solar | 1.919 MWp installed capacity; average 32% of energy consumption from rooftop solar |
These are not empty marketing sentences; there is physical investment, incentive support, machinery, and a capacity target. But what the public investor is buying is not yet proven cash flow from these facilities. What is being bought is an option written on today’s hazelnut ledger, carried with high debt.
Management language should also be watched here. In the Q1 report, the wording for Hendex’s first industrial line pointed more closely to the final quarter of 2025, and the trial line to the third quarter of 2025. The Q3 report says the first line will arrive in Turkey and be commissioned in the first quarter of 2026, with capacity increases through other lines between 2026-2028. This is not a disaster; industrial investments slip. But on a leveraged balance sheet, a calendar slip is also a financing cost.
On the corporate side, control is clear: BG Holding holds 75 percent of capital through A and B group shares, while the free float is 25 percent. The board has six members, two of them independent. In 2025, the company launched a buyback, saying the price did not reflect true performance; by early May it had reached 3.15 million shares, equal to 0.28327% of capital. The buyback amount sits on the balance sheet as 65.2 million TL of negative equity. This alone is not a major capital allocation problem; but when net debt/equity is 3.15x, every share repurchase deserves the question: debt, or support?
The Perfection the Price Demands
In the 19 May 2026 market data, the share is 13.93 TL and market capitalization is 15.49 billion TL. This price means 3.52x book value against 4.40 billion TL of equity. Add net debt, and enterprise value rises to 29.37 billion TL.
The first valuation approach is a simple multiple: 2025/9 EBITDA, calculated by adding depreciation and amortization to pre-financing operating profit, is roughly 1.64 billion TL. Enterprise value is 17.9 times that; even annualizing nine-month EBITDA gives 13.4 times. For a leveraged, commodity-input-exposed, working-capital-intensive business, this is not cheap.
The second approach is closer to the company’s own mechanics: the balance sheet bridge. By paying 15.49 billion TL, the market is pricing not only today’s equity, but also an inventory-receivables machine that 13.88 billion TL of net debt can keep turning. For this machine to run safely, the gross margin and cash conversion seen in Q3 must repeat, financing expense must not swallow gross profit, and projects must come online without expanding the need for new debt.
| Bridge | Result |
|---|---|
| Share price and market value | TRY 13.93; TRY 15.49bn |
| Enterprise value | TRY 29.37bn |
| Market value / equity | 3.52x |
| Enterprise value / 9M 2025 EBITDA | 17.9x |
| Enterprise value / annualized 9M 2025 EBITDA | 13.4x |
| Market value / annualized Q3 net profit | 5.6x |
The reason I call it expensive is not the lazy sentence “there is risk.” Every stock has risk. The issue here is that the price is too comfortable relative to the evidence left after the risk. Book value is 3.5x, enterprise value is 13.4x annualized nine-month EBITDA, and net debt is 3.15x equity. If you take Q3’s attractive net profit as the basis, the stock looks cheap; if you take the nine-month cash and debt picture as the basis, the option is not free.
What Data Would Change My Mind?
The strongest argument in BALSU’s favor is this: the company has scale, customer access, 2024 volume equal to 13 percent of Turkey’s production, Q3 gross margin rose to 16.2%, and operating cash flow turned positive. If this Q3 is not a post-harvest relief but the beginning of a new order, today’s expensive-looking enterprise value can be digested quickly. If real sales come from Hendex, capacity from Chile, and a decline from debt, the market can continue pricing the company not like a hazelnut trader, but like a scaled food platform with by-product optionality.
That is the fair counter-thesis. My objection is that this is not yet evidence; it is a condition. The next report has three clear things I will watch: is net debt falling, is cash flow from operating activities still positive after the season, and is the Hendex and Chile calendar being pushed forward again? In particular, net debt moving above 15 billion TL or operating cash turning negative again would weaken the “temporary working capital” defense for the stock. Conversely, debt falling and activated carbon sales entering the financials would soften the severity of this report.
This stock may interest a patient option investor; but it is not a growth story to buy without reading how the debt sits on top of the company. BALSU today is not a “new story with cheap multiples,” but an “expensive option waiting for proof.”
Verdict: Expensive.
Owning BALSU is not believing that a hazelnut shell will one day become carbon; it is putting money on the debt ledger not crushing the shareholder until that day arrives.